BlueRock Therapeutics’ Post

Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions https://lnkd.in/giDHRaDq

It is really exciting to see some CRISPR therapies starting to come out! This article talks more about a treatment for sickle cell disease and beta-thalassemia along with the hope of other future therapies. Read more about it here: https://lnkd.in/g6zPs9Cu #crispr #crisprtherapy

🌟 Exploring the Future of Autoimmune Disease Treatment 🌟 Read our recent blog post to learn all about the future of cell therapies in treating autoimmune conditions: https://lnkd.in/gDSy3sT5

Efficacy of venetoclax in patients with relapsed/refractory chronic lymphocytic leukaemia: analysis of the international single-arm phase 3b trial VENICE-1

New treatment options that directly address the underlying condition are needed for autoimmune diseases. As co-chair of Bristol Myers Squibb’s recently formed ACTioN, I am thrilled to connect with this group of leaders in #CARTcelltheray and #immunology at #EULAR2024 to discuss our collective goal of discovering how cell therapy can transform the treatment landscape. Visit our ACTioN page on BMS.com to learn more about the potential of cell therapy in immunology: https://rb.gy/92nksr #BMS_Employee

#Celltherapies represent a groundbreaking approach to treating a diverse spectrum of diseases, ranging from rare cancers to degenerative disorders and autoimmune conditions, by leveraging the body's own cells. However, navigating the complex journey to access these therapies can be challenging for patients, involving stringent screening, personalized treatment strategies, and vigilant monitoring for safety and efficacy. Our recent webinar delves into this intricate end-to-end process, featuring insights from two experts at Thermo Fisher Scientific. They explore how partnering with an integrated #CRO/#CDMO can streamline the development-to-manufacturing pathway, easing industry challenges and expediting patient access to life-changing treatments. Watch it here: http://spr.ly/6043b0jkZ

🌟 Exploring the Future of Autoimmune Disease Treatment 🌟 Read our recent blog post to learn all about the future of cell therapies in treating autoimmune conditions: https://lnkd.in/g-sAw5mW

📢📰In short summary, published in Transplantation and Cellular Therapy, Teclistamab appeared🦺 & effective in this real🌐heavily pre-treated RRMM patient population, where the vast majority🚫meet the eligibility criteria 4⃣ the MajesTEC-1 trial & had⬆️risk disease features. READ➡️https://lnkd.in/eJ6Zy2Re

Featured Research article from our latest JFMB 2nd issue Vol.66 concludes that:  Procalcitonin and nitric oxide may have a role in the diagnosis of acute bronchitis, in addition to lymphocytes and neutrophils. https://lnkd.in/eRf_n8Hr

Our new article has been accepted by the Journal of Oncological Sciences. In this article, we reviewed patients receiving immune checkpoint inhibitor (ICI) treatment who developed neurological adverse events. We presented the clinical spectrum, treatment approaches, and outcomes of ICI-related neurotoxicity using a case-based methodology #immunotherapy #immuncheckpointinhibitors #neurologicaladverseevents